Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of tarobtaining the DNA damage response (DDR)…
Read More
Zacharoula Sidiropoulou: Ensuring Cancer Remains at the Heart of Europe’s Health Agconcludea
Zacharoula Sidiropoulou/LinkedIn Zacharoula Sidiropoulou, Senior Consultant Breast Surgical Oncologist at Hospital São Francisco Xavier, shared a post on LinkedIn: “Join…
Read More
Australian Startup Lumonus Secures A$25 Million to Revolutionize Cancer Care with AI Technology
According to biospectrumasia.com, Australian startup Lumonus, a leader in AI-powered radiation oncology workflow solutions, has successfully closed a A$25 million…
Read More
Lumonus AI raises $25 million to embed automation in cancer care
As artificial ininformigence becomes ever more enmeshed in the healthcare system, Sydney’s Lumonus AI has raised $25 million in funding…
Read More
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outview
Stock Surge on Trial Breakthrough: Phio Pharmaceuticals’ stock soared over 100% in early trading on November 3, 2025, jumping from…
Read More
European cancer researchers release guidelines on AI apply in oncology
BERLIN — The leading professional organization for European oncologists has rolled out its first set of guidance on how its…
Read More
French startup Exeliom Biosciences boosts funding with €2.85 million to accelerate immunotherapy for cancer
Paris-based Exeliom Biosciences, a clinical-stage BioTech company developing new therapies in immuno-oncology and immuno-inflammation, today announced the completion of a…
Read More
Parliament study praises EU Cancer Plan, but laments ‘legislative inaction’
A new study commissioned by the European Parliament’s research service has praised Europe’s Beating Cancer Plan as a landmark in…
Read More
Hand sanitizer ban considered in EU over cancer risk
According to the publication, a working group at the European Chemicals Agency is considering classifying ethanol as a carcinogen. Such…
Read MoreRaludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the…
Read More
